Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity

Zhao, Dong; Wang, Yuzhen; Guo, Jing; Tian, Chuan; Pan, Wengu; Wang, Hongwei; Yan, Jieke

doi:10.2147/dddt.s366622

Cited by 10 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we found that drug release from AP/Tf-Drn/Lut NPs was slower than single ligand (AP or Tf)–decorated systems, which could be construed as more ligands the surface of the NPs perhaps reducing the release rate. The decoration of ligands on the surface of NPs may affect drug-release behavior due to their hindering effect, as concluded by Dong et al 39 The reason that drug release could not reach 100% may be due to the matrix of NPs hindering some drug release.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles

Zhu¹,

Zhang²,

Chen³

2023

DDDT

View full text Add to dashboard Cite

Objective This study aimed to develop a binary nanodrug-delivery system decorated with aptamers (APs) and transferrin (Tf) and loaded with daunorubicin (Drn) and luteolin (Lut) for the treatment of leukemia. Methods Oligonucleotide AP- and Tf-contaiing ligands were designed and synthesized separately. AP-decorated Drn-loaded nanoparticles (AP-Drn NPs) and Tf-Lut NPs were prepared by self-assembly. An AP- and Tf-codecorated Drn- and Lut-coloaded nanodrug-delivery system (AP/Tf-Drn/Lut NPs) was prepared by self-assembly of AP-Drn NPs and Tf-Lut NPs. In vitro and in vivo efficiency of the system was evaluated on leukemia cell line and cell-bearing mouse model in comparison with single ligand–decorated, single drug–loaded and free-drug formulations. Results AP/Tf-Drn/Lut NPs were spherical and nanosized (187.3±5.3 nm) and loaded with about 85% of drugs. In vitro cytotoxicity of AP/Tf-Drn/Lut NPs was remarkably higher than single ligand–decorated ones. Double drug–loaded AP/Tf-Drn/Lut NPs exhibited higher tumor-cell inhibition than single drug–loaded ones, which showed a synergic effect of the two drugs. AP/Tf-Drn/Lut NPs achieved the most efficient antileukemic activity and absence of toxicity in vivo. Conclusion The present study showed that AP/Tf-Drn/Lut NPs are a promising drug-delivery system for targeted treatment of leukemia, due to the synergic effect of the two drugs in this system. The limitations of this system include stability during large-scale production and application from bench to bedside.

show abstract

Section: Discussionmentioning

confidence: 98%

“…38 Dong et al developed hyaluronic acid-and EGFR-targeted dual peptide ligand-modified docetaxel-formononetin NPs to facilitate prostate cancer therapy. 39 In the present research, we developed AP/Tf-Drn/Lut NPs for leukemia therapy. AP/Tf-Drn/Lut NPs were 187 nm in size.…”

Section: Discussionmentioning

confidence: 99%

Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles

Zhu¹,

Zhang²,

Chen³

2023

DDDT

View full text Add to dashboard Cite

show abstract

“…Formonetin (FMN) is an effective ingredient extracted from Trifolium pratense and Astragalus membranaceus, which can be used to treat castration-tolerant prostate cancer ( Tay et al, 2019 ). To improve the synergistic anti-cancer effects, Dong et al ( Dong et al, 2022 ) used HA and GE as the carrier of FMN and DTX, respectively, and self-assembled the two carriers to prepare binary nanoparticles (HA/GE-DTX/FMN NP). The results showed that the particle size of HA/GE-DTX/FMN nanoparticles was 190 nm, and the zeta potential was 20 mV.…”

Section: Polymer-based Nanocarriers For Co-deliverymentioning

confidence: 99%

Nanoparticle drug delivery systems for synergistic delivery of tumor therapy

Chen

Liu²,

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Nanoparticle drug delivery systems have proved anti-tumor effects; however, they are not widely used in tumor therapy due to insufficient ability to target specific sites, multidrug resistance to anti-tumor drugs, and the high toxicity of the drugs. With the development of RNAi technology, nucleic acids have been delivered to target sites to replace or correct defective genes or knock down specific genes. Also, synergistic therapeutic effects can be achieved for combined drug delivery, which is more effective for overcoming multidrug resistance of cancer cells. These combination therapies achieve better therapeutic effects than delivering nucleic acids or chemotherapeutic drugs alone, so the scope of combined drug delivery has also been expanded to three aspects: drug-drug, drug-gene, and gene-gene. This review summarizes the recent advances of nanocarriers to co-delivery agents, including i) the characterization and preparation of nanocarriers, such as lipid-based nanocarriers, polymer nanocarriers, and inorganic delivery carriers; ii) the advantages and disadvantages of synergistic delivery approaches; iii) the effectual delivery cases that are applied in the synergistic delivery systems; and iv) future perspectives in the design of nanoparticle drug delivery systems to co-deliver therapeutic agents.

show abstract

“…These hydroxyls are also able to chelate metal ions and, thus, hamper the metal-catalyzed generation of reactive oxygen substances (ROS) and their oxidant activity. According to our research of the literature, the flavonoids that have been included in HA-coated delivery nanosystems investigated against cancer in the last 5 years are the two flavonols: kaempferol [34] and quercetin (QU) [35][36][37][38][39][40][41], the flavanol epigallocatechin-3-gallate (EGCG) [42][43][44][45][46][47] the flavanone naringenin [48], the isoflavone formononetin [49], and a mix of anthocyanins extracted from corn [50]. Between brackets are reported the number of compounds belonging to each class or subclass according to this classification.…”

Section: Phecs Included In Drug Nanodelivery Systems For Tumor Targetingmentioning

confidence: 99%

“…Thus, in this case, QU was the only anticancer agent delivered to the very aggressive 4T1 triple-negative breast cancer (TNBC) mouse cells grown in vitro or transplanted in syngeneic immunocompetent Balbc/mice. In vitro: ↓ PC3 cell viability In vivo: ↓ Tumor volume ↑ Drug distribution in tumor [49] CD/QU: 2-hydroxypropyl-β-cyclodextrin/Quercetin; CTGF: connective tissue growth factor; CU: curcumin; DOX: doxorubicin; DXT: docetaxel; EGCG: epigallocatechin-3-gallate; HA: hyaluronic acid; KA: kaempferol; MDR: multidrug resistance; NP: nanoparticles; PEI-TOS/HA-QU: Polyethyleneimine-Tocopherol Hydrogen Succinate/Hyaluronic Acid-Quercetin; PTX: paclitaxel; QU: Quercetin; TPGS: D-Alpha-tocopheryl polyethylene glycol 1000 succinate.…”

Section: Ha-based Nanocarrier Systems Loading Flavonoidsmentioning

confidence: 99%

Hyaluronic Acid-Mediated Phenolic Compound Nanodelivery for Cancer Therapy

et al. 2023

View full text Add to dashboard Cite

Phenolic compounds are bioactive phytochemicals showing a wide range of pharmacological activities, including anti-inflammatory, antioxidant, immunomodulatory, and anticancer effects. Moreover, they are associated with fewer side effects compared to most currently used antitumor drugs. Combinations of phenolic compounds with commonly used drugs have been largely studied as an approach aimed at enhancing the efficacy of anticancer drugs and reducing their deleterious systemic effects. In addition, some of these compounds are reported to reduce tumor cell drug resistance by modulating different signaling pathways. However, often, their application is limited due to their chemical instability, low water solubility, or scarce bioavailability. Nanoformulations, including polyphenols in combination or not with anticancer drugs, represent a suitable strategy to enhance their stability and bioavailability and, thus, improve their therapeutic activity. In recent years, the development of hyaluronic acid-based systems for specific drug delivery to cancer cells has represented a pursued therapeutic strategy. This is related to the fact that this natural polysaccharide binds to the CD44 receptor that is overexpressed in most solid cancers, thus allowing its efficient internalization in tumor cells. Moreover, it is characterized by high biodegradability, biocompatibility, and low toxicity. Here, we will focus on and critically analyze the results obtained in recent studies regarding the use of hyaluronic acid for the targeted delivery of bioactive phenolic compounds to cancer cells of different origins, alone or in combination with drugs.

show abstract

Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity

Cited by 10 publications

References 45 publications

Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles

Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles

Nanoparticle drug delivery systems for synergistic delivery of tumor therapy

Hyaluronic Acid-Mediated Phenolic Compound Nanodelivery for Cancer Therapy

Contact Info

Product

Resources

About